Ipsen and Sutro Biopharma Collaborate to Develop and Commercialize STRO-003 for Treating Solid Tumors
Shots:
- Ipsen and Sutro have entered into an exclusive global licensing agreement under which the former gains an exclusive worldwide right for the development & commercialization of STRO-003
- As per the collaboration, Ipsen will handle the IND submission, clinical development and commercialization activities of STRO-003 while Sutro is entitled to receive a payment of ~$900M as upfront, development, regulatory & commercial milestones incl. ~$90M in near-term payments (equity investment) & global sales-based tiered royalties
- STRO-003 is an ADC targeting ROR1 that demonstrated favorable efficacy and safety in preclinical studies for both solid tumors and hematological malignancies
Ref: Sutro | Image: Ipsen
Related News:- Ipsen’s Sohonos (palovarotene) Receives the US FDA’s Approval for Fibrodysplasia Ossificans Progressiva
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
